Globus Medical
Market Cap
US$5.1b
Last Updated
2019/09/16 00:14 UTC
Data Sources
Company Financials +
Executive Summary
Globus Medical, Inc., a medical device company, focuses on the design, development, and commercialization of musculoskeletal implants that promote healing in patients with spine disorders.
Snowflake
Fundamentals
Flawless balance sheet with moderate growth potential.
Similar Companies
Share Price & News
How has Globus Medical's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
4.2%
NYSE:GMED
-0.9%
US Medical Equipment
1.3%
US Market
1 Year Return
-1.7%
NYSE:GMED
9.1%
US Medical Equipment
2.0%
US Market
GMED underperformed the Medical Equipment industry which returned 8.7% over the past year.
GMED underperformed the Market in United States of America which returned 1.7% over the past year.
Share holder returns
| GMED | Industry | Market | |
|---|---|---|---|
| 7 Day | 4.2% | -0.9% | 1.3% |
| 30 Day | 2.8% | 0.7% | 3.9% |
| 90 Day | 21.9% | 4.4% | 3.4% |
| 1 Year | -1.7%-1.7% | 10.0%9.1% | 4.2%2.0% |
| 3 Year | 128.5%128.5% | 70.7%65.5% | 47.2%37.6% |
| 5 Year | 161.9%161.9% | 130.7%104.3% | 60.5%42.9% |
Price Volatility Vs. Market
How volatile is Globus Medical's share price compared to the market and industry in the last 5 years?
Simply Wall St News
4 days ago | Simply Wall St
Did Business Growth Power Globus Medical's (NYSE:GMED) Share Price Gain of 154%?2 weeks ago | Simply Wall St
Here's Why I Think Globus Medical (NYSE:GMED) Is An Interesting Stock4 weeks ago | Simply Wall St
Does Globus Medical, Inc. (NYSE:GMED) Create Value For Shareholders?Valuation
Is Globus Medical undervalued based on future cash flows and its price relative to the stock market?
35.19x
Price to Earnings (PE) ratio
Intrinsic Value Based on Future Cash Flows
Globus Medical's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
Globus Medical's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
Price Based on Earnings
Globus Medical is good value based on earnings compared to the US Medical Equipment industry average.
Globus Medical is overvalued based on earnings compared to the United States of America market.
Price Based on Expected Growth
Globus Medical is poor value based on expected growth next year.
Price Based on Value of Assets
Globus Medical is good value based on assets compared to the US Medical Equipment industry average.
Next Steps
Future Growth
How is Globus Medical expected to perform in the next 1 to 3 years based on estimates from 13 analysts?
14.3%
Forecasted annual earnings growth
Earnings and Revenue Growth Estimates
Future Annual Growth Analysis
Globus Medical's revenue is expected to grow by 8.4% yearly, however this is not considered high growth (20% yearly).
Globus Medical's earnings are expected to grow by 14.3% yearly, however this is not considered high growth (20% yearly).
Globus Medical's revenue growth is expected to exceed the United States of America market average.
Globus Medical's earnings growth is expected to exceed the United States of America market average.
Globus Medical's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Earnings per Share Growth Estimates
Future Return on Equity
Globus Medical is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
Next Steps
Past Performance
How has Globus Medical performed over the past 5 years?
10.2%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Globus Medical's year on year earnings growth rate has been positive over the past 5 years.
Globus Medical's 1-year earnings growth is less than its 5-year average (6.6% vs 10.2%)
Globus Medical's earnings growth has not exceeded the US Medical Equipment industry average in the past year (6.6% vs 28.9%).
Return on Equity
Globus Medical has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
Return on Assets
Globus Medical used its assets more efficiently than the US Medical Equipment industry average last year based on Return on Assets.
Return on Capital Employed
Globus Medical's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
Next Steps
Financial Health
How is Globus Medical's financial position?
Financial Position Analysis
Globus Medical is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Globus Medical's cash and other short term assets cover its long term commitments.
Debt to Equity History and Analysis
Globus Medical has no debt.
Globus Medical has not taken on any debt in the past 5 years.
Globus Medical has no debt, it does not need to be covered by operating cash flow.
Globus Medical has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
High level of physical assets or inventory.
Globus Medical has no debt, it does not need to be covered by short term assets.
Next Steps
Dividend
What is Globus Medical's current dividend yield, its reliability and sustainability?
Dividend Yield and Payments Analysis
Unable to evaluate Globus Medical's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
Unable to evaluate Globus Medical's dividend against the top 25% market benchmark as the company has not reported any payouts.
Unable to perform a dividend volatility check as Globus Medical has not reported any payouts.
Unable to verify if Globus Medical's dividend has been increasing as the company has not reported any payouts.
Current Payout to Shareholders
Unable to calculate sustainability of dividends as Globus Medical has not reported any payouts.
Future Payout to Shareholders
No need to calculate the sustainability of Globus Medical's dividends in 3 years as they are not expected to pay a notable one for United States of America.
Next Steps
Management
What is the CEO of Globus Medical's salary, the management and board of directors tenure and is there insider trading?
1.9yrs
Average management tenure
CEO
Dave Demski (61yo)
2.1yrs
Tenure
US$3,394,012
Compensation
Mr. David M. Demski, also known as Dave, has been the Chief Executive Officer of Globus Medical, Inc. since August 29, 2017 and has been its President since April 2019. Mr. Demski served as Group President ...
CEO Compensation Analysis
Dave's remuneration is lower than average for companies of similar size in United States of America.
Dave's compensation has been consistent with company performance over the past year, both up more than 20%.
Management Age and Tenure
1.9yrs
Average Tenure
52yo
Average Age
The average tenure for the Globus Medical management team is less than 2 years, this suggests a new team.
Board Age and Tenure
8.4yrs
Average Tenure
58yo
Average Age
The tenure for the Globus Medical board of directors is about average.
Insider Trading
No 3 month open market individual insider trading information.
Ownership Breakdown
Management Team
Brian Kearns (52yo)
Senior Vice President of Business Development & Investor Relations
- Tenure: 0yrs
Dave Demski (61yo)
CEO, President & Director
- Tenure: 2.1yrs
- Compensation: US$3.39m
David Paul (52yo)
Co-Founder & Executive Chairman
- Tenure: 16.7yrs
- Compensation: US$2.25m
Mike Reeder
Executive Officer
- Tenure: 12.3yrs
Richard Holifield
Executive Officer
- Tenure: 12.3yrs
A. Murphy (54yo)
Executive Vice President of International Sales
- Tenure: 1.7yrs
- Compensation: US$1.31m
Steven Payne (48yo)
VP & Controller
- Tenure: 0.08yrs
Dan Scavilla (54yo)
Executive VP & Chief Commercial Officer
- Tenure: 0.08yrs
- Compensation: US$1.88m
Keith Pfeil (39yo)
Senior VP & CFO
- Tenure: 0.08yrs
Kelly Huller
Senior VP
- Tenure: 0yrs
Board Members
Ann Rhoads (54yo)
Director
- Tenure: 8.2yrs
- Compensation: US$400.58k
Steve Zarrilli (58yo)
Director
- Tenure: 0.3yrs
Jim Tobin (74yo)
Director
- Tenure: 4.1yrs
- Compensation: US$390.58k
Dave Demski (61yo)
CEO, President & Director
- Tenure: 2.1yrs
- Compensation: US$3.39m
David Paul (52yo)
Co-Founder & Executive Chairman
- Tenure: 16.7yrs
- Compensation: US$2.25m
David Davidar (53yo)
Director
- Tenure: 16.5yrs
- Compensation: US$370.58k
Dan Lemaitre (65yo)
Director
- Tenure: 8.4yrs
- Compensation: US$388.08k
Company Information
Globus Medical, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Globus Medical, Inc.
- Ticker: GMED
- Exchange: NYSE
- Founded: 2003
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$5.066b
- Shares outstanding: 99.10m
- Website: https://www.globusmedical.com
Number of Employees
Location
- Globus Medical, Inc.
- 2560 General Armistead Avenue
- Audubon
- Pennsylvania
- 19403
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| GMED | NYSE (New York Stock Exchange) | Yes | Class A Common Stock | US | USD | Aug 2012 |
| GM0N | DB (Deutsche Boerse AG) | Yes | Class A Common Stock | DE | EUR | Aug 2012 |
| GMED * | BMV (Bolsa Mexicana de Valores) | Yes | Class A Common Stock | MX | MXN | Aug 2012 |
Biography
Globus Medical, Inc., a medical device company, focuses on the design, development, and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The company offe ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/09/16 00:14 |
| End of Day Share Price | 2019/09/13 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.